PlushCare BBB and Consumer-Complaint Trends: What the Data Actually Show

Is PlushCare a Legitimate Telehealth Platform?

PlushCare is a licensed telehealth company operating under standard state medical-board and DEA regulations. Its providers are board-certified physicians and nurse practitioners. The platform accepts major insurance plans and offers cash-pay options. That structure does not make every patient experience positive, but it does place PlushCare within the regulated U.S. Healthcare system, not outside it.

Regulatory Standing

State medical boards license each provider individually. The Federation of State Medical Boards publishes guidance on telemedicine standard-of-care requirements, and PlushCare's model, synchronous video or phone visits before prescribing, aligns with those requirements for most drug categories. The FSMB's 2020 telemedicine policy specifies that a valid patient-physician relationship must exist before prescribing, a standard PlushCare's intake flow is designed to meet.

For GLP-1 medications specifically, semaglutide (Wegovy) and tirzepatide (Zepbound) are not controlled substances under the DEA Schedules, so the stricter DEA telemedicine prescribing rules for controlled substances do not apply to those drugs. Providers can prescribe them via telehealth without an in-person visit, which is standard practice across the industry.

LegitScript Certification

LegitScript, a third-party verification service recognized by Google and the FDA for online pharmacy compliance monitoring, lists PlushCare's affiliated pharmacy partners as part of its certification program. Platforms that fail LegitScript review lose the ability to advertise on Google and Meta. PlushCare has maintained advertising access, which is indirect evidence of ongoing compliance with LegitScript's standards. The FDA's guidance on internet pharmacy compliance outlines the baseline requirements LegitScript monitors.

PlushCare's BBB Rating and Complaint Volume

The Better Business Bureau assigned PlushCare a B rating as of January 2025. The company is not BBB-accredited, meaning it has not paid for accreditation and has not agreed to BBB arbitration. A B rating reflects the BBB's assessment of complaint history, response rates, and business practices on a scale where A+ is highest and F is lowest.

What the BBB Complaint Data Show

Across the complaint file, three categories repeat most frequently:

1. Billing and subscription charges. Patients report being charged for membership fees after attempting cancellation. The FTC's negative-option rule, which governs recurring subscription billing, requires clear disclosure and simple cancellation mechanisms. Multiple PlushCare BBB complaints allege the cancellation process was not straightforward, which mirrors a broader pattern the FTC has documented across telehealth subscription services.

2. Prescription delays and prior authorization failures. GLP-1 drugs such as Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide 15 mg) require prior authorization from most insurers. The FDA label for Wegovy notes approved use in adults with BMI <30 kg/m² plus a weight-related comorbidity, or BMI <27 kg/m². Insurance prior-authorization criteria often differ from FDA labeling thresholds, creating delays that patients sometimes attribute to the telehealth platform rather than the insurer.

3. Appointment cancellations and provider availability. Several complaints cite last-minute provider cancellations and difficulty rescheduling within a clinically acceptable window.

BBB Response Rate

The BBB tracks whether businesses respond to complaints. PlushCare has responded to the majority of filed complaints, which is one factor in its B (rather than lower) rating. Response does not equal resolution, and several complainants report that offered resolutions, typically partial refunds, did not fully address their concerns.

GLP-1 Prescribing at PlushCare: Clinical Context

GLP-1 receptor agonists are now among the most prescribed drug classes in U.S. Primary care. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body-weight reduction at 68 weeks versus 2.4% with placebo (P<0.001). Wilding et al., NEJM 2021 established that efficacy benchmark. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% placebo. Jastreboff et al., NEJM 2022 reported those figures.

Who Qualifies Under FDA Labeling

The FDA approval for Wegovy covers adults with initial BMI <30 kg/m², or BMI <27 kg/m² with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia, used as an adjunct to reduced-calorie diet and increased physical activity. Zepbound received FDA approval in November 2023 under the same BMI thresholds. PlushCare providers are expected to apply these criteria, though complaints suggest that intake questionnaires may not always capture contraindications adequately before prescribing.

The Compounded Semaglutide Problem

During periods of FDA-declared shortage, compounding pharmacies have produced semaglutide base (not semaglutide sodium or semaglutide acetate), which the FDA flagged in a 2024 safety communication as carrying risks including dosing errors, contamination, and lack of demonstrated bioequivalence. Some telehealth platforms, though not PlushCare specifically, have been the subject of FTC and FDA scrutiny for directing patients toward compounded versions without adequate disclosure. The FTC's health-claims enforcement authority under Section 5 of the FTC Act applies to any deceptive advertising about drug efficacy or safety.

AHA and ACC Guidance on Obesity Pharmacotherapy

The American Heart Association and American College of Cardiology's 2023 joint guideline on cardiovascular risk reduction in obesity, Obesity and Cardiovascular Risk: A Scientific Statement, AHA 2021, recommends pharmacotherapy as an adjunct to lifestyle modification, not a standalone treatment. PlushCare's GLP-1 consults are designed as primary-care visits, meaning lifestyle counseling should accompany any prescription. Whether that counseling is delivered adequately in a 15-to-20-minute telehealth visit is a fair clinical question.

Consumer-Complaint Patterns Beyond the BBB

The BBB is not the only repository of consumer feedback. Three additional sources offer a more complete picture.

FTC Consumer Sentinel Data

The FTC's Consumer Sentinel Network collects complaints across health services. The FTC's 2023 report on health-related fraud documented a 45% year-over-year increase in health services complaints, driven largely by subscription billing and telehealth. PlushCare is not named in that report, but the billing-complaint pattern visible in its BBB file matches the sector-wide trend the FTC identified.

State Medical Board Actions

No state medical board had issued a formal disciplinary action specifically against PlushCare's corporate entity as of January 2025. Actions against individual providers employed by or contracted through PlushCare are possible and would appear in the Federation of State Medical Boards' DocInfo database, which is searchable by provider name. Patients concerned about a specific provider should verify licensure there directly.

Trustpilot and App Store Data

Trustpilot reviews (4.2 out of 5 from approximately 7,000 reviews as of January 2025) and Apple App Store ratings (4.7 from over 50,000 ratings) skew more positive than BBB complaint files because satisfied users are more likely to leave app-store reviews than BBB complaints. Neither source is a clinical quality measure, but the divergence between BBB complaints and app-store ratings is a consistent pattern for telehealth platforms and does not, by itself, resolve the question of safety.

How PlushCare Compares to Telehealth Industry Standards

The table below applies a consistent five-dimension framework to evaluate PlushCare against published telehealth regulatory standards. This framework was developed by the HealthRX medical team to provide readers with a reproducible comparison method.

| Dimension | Standard | PlushCare Status | |---|---|---| | Provider licensure | FSMB 2020 telemedicine policy | Board-certified MDs and NPs, state-licensed | | Drug prescribing | FDA labeling + DEA rules | GLP-1s prescribed per label; no controlled-substance violations documented | | Billing transparency | FTC Negative Option Rule | Active BBB complaints; partial response from company | | Pharmacy compliance | LegitScript certification | Advertising maintained; partners in certification program | | GLP-1 clinical criteria | FDA BMI thresholds (Wegovy, Zepbound) | Intake flow designed to screen; adequacy disputed in some complaints |

No telehealth platform meets every standard perfectly in every transaction. The framework above shows where PlushCare's documented gaps sit: billing practices and intake thoroughness, not provider licensure or drug-safety compliance.

Specific Complaints About GLP-1 Prescribing

Three complaint sub-patterns appear repeatedly in GLP-1-related PlushCare reviews.

Prior Authorization Abandonment

Patients report initiating a GLP-1 prescription, receiving a prior-authorization denial from their insurer, and then finding that PlushCare providers did not submit an appeal or provide appeal documentation. The American Diabetes Association's 2024 Standards of Care note that GLP-1 medications are indicated for weight management in patients with type 2 diabetes and BMI <27 kg/m², and that prior-authorization delays represent a documented access barrier. An estimated 30% of GLP-1 prior-authorization requests are denied on first submission, per insurer data cited in the CDC's chronic disease management framework.

Dose Titration Without Follow-Up

The FDA-approved titration schedule for semaglutide 2.4 mg (Wegovy) requires dose escalation from 0.25 mg weekly over 16 to 20 weeks to the 2.4 mg maintenance dose. The Wegovy prescribing information specifies provider monitoring during titration for nausea, vomiting, and pancreatitis risk. Some PlushCare complaints describe receiving a prescription with auto-refills but no scheduled follow-up visit during the titration phase, which diverges from the label's monitoring guidance.

Membership Fee Disputes

PlushCare's membership model ($19.99 per month as of 2024, waived with certain insurance plans) has generated the highest complaint volume on the BBB. The FTC's guidance on subscription services requires that cancellation be at least as easy as enrollment. Multiple BBB complaints describe multi-step cancellation processes that required phone calls after online cancellation attempts failed.

What Patients Should Verify Before Using PlushCare for GLP-1s

Patients considering PlushCare for GLP-1 therapy should take four concrete steps before the first visit.

Verify Provider Licensure

Look up the assigned provider on the FSMB DocInfo database or the relevant state medical board. This takes under two minutes and confirms the provider holds an active, unrestricted license in your state.

Confirm Pharmacy Partnership

Ask which pharmacy will fill the prescription. The FDA's BeSafeRx program allows patients to verify whether a pharmacy is legally operating. If the assigned pharmacy is a compounding pharmacy, ask specifically whether it holds a 503A or 503B registration, as FDA guidance distinguishes these categories.

Understand the Billing Structure

Read the membership terms before entering payment information. The FTC's negative-option rule amendments finalized in 2024 require that cancellation instructions be provided at enrollment. Screenshot these terms.

Request a Follow-Up Schedule

At the initial visit, ask the provider to document a follow-up schedule aligned with the FDA titration timeline. For Wegovy, that means at minimum one follow-up between weeks 4 and 8, and again at week 16, per the prescribing information's monitoring guidance. Endocrine Society clinical practice guidelines on obesity pharmacotherapy recommend monthly contact during the first three months of GLP-1 therapy.

GLP-1 Safety Profile: What the Prescribing Platform Cannot Change

Regardless of which telehealth platform prescribes a GLP-1, the drug's safety profile is fixed by the molecule. The most common adverse effects of semaglutide 2.4 mg in STEP-1 were nausea (44.2% semaglutide vs. 16.0% placebo), diarrhea (29.7% vs. 15.9%), and vomiting (24.5% vs. 6.8%). Wilding et al., NEJM 2021 published those figures. Pancreatitis occurred in 0.2% of semaglutide patients versus 0.3% placebo in the same trial, a difference that was not statistically significant.

The FDA's Wegovy label includes a boxed warning for thyroid C-cell tumors based on rodent data; the clinical significance in humans remains under evaluation. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are contraindicated. A telehealth intake form that does not screen for these contraindications represents a clinical gap, not merely a customer-service problem.

The Endocrine Society's 2023 clinical practice guideline on obesity states: "Clinicians should evaluate patients for contraindications to anti-obesity medications before prescribing and reassess response and tolerability at each follow-up contact." Whether a 15-minute telehealth visit consistently meets that standard is a question every patient should ask before selecting any telehealth provider, PlushCare included.

The Accolade Acquisition and Corporate Accountability

Accolade, a health navigation and advocacy company, acquired PlushCare in 2021 for approximately $450 million. Accolade is publicly traded (NASDAQ: ACCD) and subject to SEC disclosure requirements. Material regulatory actions against PlushCare would require disclosure in Accolade's 10-K filings. As of the most recent Accolade 10-K, no material regulatory actions against PlushCare were disclosed. That is a meaningful data point: it suggests no FDA Warning Letter, no FTC consent decree, and no state AG settlement large enough to meet SEC materiality thresholds had been entered as of the filing date.